Director — Kelly Ulto, Greg Shilling: Election and re-election of directors to the Board and appointment to various committees.

Other Events On July 24, 2026, Milestone Scientific Inc. (the “Company”) received notices of conversion (the “Conversion Notices”) from Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman, each of whom is a director of the Company (collectively, the “Holders”), with respect to the Company’s amended and restated promissory notes held by the Holders (the “Convertible Bridge Notes”). As previously disclosed, the Convertible Bridge Notes were originally issued in an aggregate principal amou…

Regulation FD Disclosure The Company issued a press release on June 25, 2026, announcing the restructuring of the Board, including the appointment of Kelly Ulto and Greg Shilling as independent directors of the Company, and the election of Benedetta Casamento as Executive Chairman. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Director — Shanth Thiyagalingam: Shanth Thiyagalingam resigned as a director to focus on his other commitments.

Entry into a Material Definitive Agreement On June 19, 2026, Milestone Scientific Inc. (the “Company”) entered into an agreement (the “New Osser Agreement”) effective as of April 1, 2026 (the “Effective Date”) with Leonard Osser (“Osser”), a former Chairman and Chief Executive Officer of the Company and currently the Managing Director, China Operations of the Company, and U.S. Asian Consulting Group (“U.S. Asian”), a company of which Osser is a principal and together with his wife the sole me…

Changes in Registrant’s Certifying Accountant On April 30, 2026, the Board of Directors of Milestone Scientific Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ CPAs”) as the independent registered public accounting firm to the Company effective as of May 15, 2026. The Company engaged Grassi & Co., CPAs, P.C. to be the independent registered public accounting firm to the Company for the fiscal year ending December 31, 2026. The approval of the dismissal of CBIZ CPAs was ap…

The filing describes a stock option exchange program for certain executives, which is not a management change.

Unregistered Sales of Equity Securities The disclosures set forth in

Entry into a Material Definitive Agreement On April 20, 2026, Milestone Scientific Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 7,962,963 units (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) one warrant to purchase one share…

Entry into a Material Definitive Agreement On March 31, 2026, Milestone Scientific Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Amended and Restated Memorandum of Understanding, dated January 13, 2026 (the “MOU”), with Innovest S.p.A., as the holder of certain consent/blockage rights with respect to BP4 S.r.l., a society’ a responsibility’ limitation in liquidation (“BP4”). According to BP4, it was then the owner of 11.31% of the outstanding shares of common stock o…

Entry into a Material Agreement On January 15, 2026, Milestone Scientific Inc. (“the Company”) entered into an Amended and Restated Memorandum of Understanding (the “MOU”) with Innovest S.p.A., as the holder of certain consent/blockage rights with respect to BP4 S.r.l., a society’ a responsibility’ limitation in liquidation (“BP4”). According to BP4, it was then the owner of 11.31% of the outstanding shares of common stock of the Company. BP4 agreed, among other things, subject to certain con…

Director — Mr. Leonard A. Osser: Mr. Osser resigned as a director of the company, but will continue to be involved through his employment and consulting agreements.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On October 8, 2025, Milestone Scientific Inc. (“the Company”) received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the Company is not in compliance with the continued listing standards as outlined in Section(s) 1003(a)(ii), and (iii) of the NYSE American Company Guide (the “Company Guide”). To maintain its listing, the Company must submit a plan of complianc…

President and Chief Executive Officer, Director — Eric Hines: Eric Hines was appointed as President and Chief Executive Officer, and as a director of the Company.

Director — Shanth Thiyagalingam: The company appointed an experienced executive as an independent director.

Changes in Registrant ’ s Certifying Accountant Based on information provided by Marcum LLP ("Marcum"), the independent registered public accounting firm of Milestone Scientific Inc. (the "Company"), CBIZ CPAs P.C. ("CBIZ CPAs") acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company's independent registered public accounting firm through April 22, 2025. On April 22, 2025, Marcum resigned as the Company's independent registered public accou…

Director — Mr. Giandomenico Trombetta: Resigned due to personal reasons and need to attend to other matters.

Chief Executive Officer — Mr. Arjan Haverhals: Mr. Haverhals intends to retire as an officer but will continue as a director and consultant.

Entry into a Material Definitive Agreement Milestone Scientific Inc. (the “Company”) was approved on September 12, 2023, to participate in the State of New Jersey Emerging Technology and Biotechnology Financial Assistance Program (the “Program”). The program is designed to provide funds to new or expanding technology and biotechnology companies by allowing those companies with unused Net Operating Loss (“NOL”) Carryover and/or Unused Research and Development (“R & D”) Tax Credits to transfer…

Entry into a Material Definitive Agreement On December 10, 2023, Milestone Scientific Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Maxim Group LLC, acting as sole underwriter and book-running manager (the “Underwriter”), for a public offering (the “Offering”) of an aggregate of 4,765,000 shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company. The public offering price for each share of Common Stock was $0.63, a…

Entry into a Material Definitive Agreement On December 10, 2023, Milestone Scientific Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Maxim Group LLC, acting as sole underwriter and book-running manager (the “Underwriter”), for a public offering (the “Offering”) of an aggregate of 4,765,000 shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company. The public offering price for each share of Common Stock was $0.63. T…

Director — Dr. Didier Demesmin: The company appointed Dr. Didier Demesmin as an independent director.

Chief Financial Officer — Peter J. Milligan: Mr. Milligan resigned to pursue other interests.

Arjan Haverhals: The amendment extended the severance benefits period for the CEO.

Chief Financial Officer — Peter Milligan: Mr. Milligan was appointed as the Company’s Chief Financial Officer.